Using Moses 2.0 technology for prostate laser treatment
Moses Vaporization: Is Use of Moses 2.0 in Holmium Laser Ablation of the Prostate More Efficient
NA · University of Kansas Medical Center · NCT04979143
This study is testing if a new technology called Moses 2.0 can make laser treatment for an enlarged prostate work better for patients.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 124 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University of Kansas Medical Center (other) |
| Locations | 1 site (Kansas City, Kansas) |
| Trial ID | NCT04979143 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the efficiency of the Moses 2.0 technology during holmium laser vaporization of the prostate for patients with benign prostatic hyperplasia. Patients will undergo standard preoperative assessments and will be randomized to receive either the standard laser treatment or the treatment enhanced with Moses 2.0 technology. The study will measure various intraoperative parameters, including procedure time and vaporization efficiency, while ensuring that both the surgeon and patient are blinded to the treatment received. Virtual appointments may be offered for certain aspects of the trial to accommodate the ongoing COVID-19 pandemic.
Who should consider this trial
Good fit: Ideal candidates are men over 18 years old with bothersome lower urinary tract symptoms who choose surgical management and have a prostate size of 60 grams or less.
Not a fit: Patients with a current diagnosis of prostate cancer, urinary retention, or those on anticoagulation therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more efficient and effective treatment options for patients suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving surgical outcomes with advanced laser technologies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \> 18 years of age * Patients with bothersome lower urinary tract symptoms who opt for surgical management * Prostate size 60g or less Exclusion Criteria: * Current use of anticoagulation or antiplatelet agent Aspirin 81 use is okay and can be continued through the study * Bleeding diathesis * AUA symptom score \< 9 * Current urinary retention * Known diagnosis of prostate cancer * Known diagnosis of neurogenic bladder
Where this trial is running
Kansas City, Kansas
- University of Kansas Medical Center — Kansas City, Kansas, United States (RECRUITING)
Study contacts
- Principal investigator: Donald Neff — University of Kansas Medical Center
- Study coordinator: Jane Ledesma
- Email: jledesma2@kumc.edu
- Phone: 19135888721
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms